Cargando…

Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells

Lapatinib is an inhibitor of human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-25% of breast cancers. Clinically, lapatinib has shown promising benefits for HER2-positive breast cancer patients; however, patients eventually acquire resistance, limiting its long-term use....

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Wei-Chien, Hung, Chao-Ming, Wei, Ching-Ting, Chen, Tsung-Ming, Chien, Pei-Hsuan, Pan, Hsiao-Lin, Lin, Yueh-Ming, Chen, Yun-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308732/ https://www.ncbi.nlm.nih.gov/pubmed/27694691 http://dx.doi.org/10.18632/oncotarget.11471

Ejemplares similares

Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6
por: Hsiao, Yu-Chun, et al.
Publicado: (2015)

Hepatitis B Virus X Upregulates HuR Protein Level to Stabilize HER2 Expression in Hepatocellular Carcinoma Cells
por: Hung, Chao-Ming, et al.
Publicado: (2014)

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
por: Chen, Yun-Ju, et al.
Publicado: (2013)

miR‐221 confers lapatinib resistance by negatively regulating p27(kip1) in HER2‐positive breast cancer
por: Huynh, Thanh Kieu, et al.
Publicado: (2021)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
por: Wang, Bo-Wei, et al.
Publicado: (2021)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin
por: Lin, Yueh-Ming, et al.
Publicado: (2018)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Trichostatin A Suppresses EGFR Expression through Induction of MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells
por: Tu, Chih-Yen, et al.
Publicado: (2014)

miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin
por: Chen, Wen-Shu, et al.
Publicado: (2015)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Utilizing apolipoprotein E genotypes and associated comorbidities for the assessment of the risk for dementia
por: Tung, Hsin, et al.
Publicado: (2022)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER2 phosphorylation at Thr701
por: Chen, Chia‐Hung, et al.
Publicado: (2017)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
por: Chen, Zhe-Ling, et al.
Publicado: (2016)

Association Study between Novel CYP26 Polymorphisms and the Risk of Betel Quid-Related Malignant Oral Disorders
por: Wu, Shyh-Jong, et al.
Publicado: (2015)

Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15
por: Lin, Syh-Jae, et al.
Publicado: (2020)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Synergistic Tumor Inhibition via Energy Elimination by Repurposing Penfluridol and 2-Deoxy-D-Glucose in Lung Cancer
por: Lai, Tsung-Ching, et al.
Publicado: (2022)

Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs
por: Chien, Ming-Hsien, et al.
Publicado: (2013)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma
por: Chen, Yu-Syuan, et al.
Publicado: (2022)

Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection
por: Hung, Ting-Chun, et al.
Publicado: (2018)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Dynamic ultrasound molecular‐targeted imaging of senescence in evaluation of lapatinib resistance in HER2‐positive breast cancer
por: Chen, Xiaoyu, et al.
Publicado: (2023)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022)

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
por: Tsai, Yi-Giien, et al.
Publicado: (2023)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Arthropod Bite-Like Eruption as Rare Presentation of Secondary Syphilis in an HIV-Infected Patient
por: Chen, Chih-Yu, et al.
Publicado: (2020)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_niugh5iifot5vuu8046c9v9aio